2) Now we are covering @IASLC #WCLC22 updates on #KRAS_mutated #LCSM! Our author is Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert @KRASKickers pic.twitter.com/mDydm9D2vs
— @onc_ce (@onc_ce) August 16, 2022
4a) #KRAS discovered in 1980s with immediate implications for #cancer, but remained “undruggable” til 2021 with first @FDAOncology approval, for KRASG12c #LCSM! pic.twitter.com/xH5g4DQr8w
— @onc_ce (@onc_ce) August 16, 2022
5) 2⃣ leading #KRASG12C ➖ #Sotorasib and #Adagrasib, with others in development. At @IASLC #WCLC22 we saw data on #sotorasib with #immunotherapy & #SHP2 inhibitor & new #KRASG12C inhibitors GDC-6036, & D-1553! @HemOncFellows @Oncbrothers #LCSM pic.twitter.com/pkYrsjByzT
— @onc_ce (@onc_ce) August 16, 2022
7a) OA03.01 #Sotorasib + RMC-4630 arm of #CodeBreak100, from Dr. Falchok @SarahCannonDocs @IASCL #WCLC22
— @onc_ce (@onc_ce) August 16, 2022
Phase 1b: Dose Exploration (n=27), included #LCSM, #CRCSM and other tumors
Background info #CodeBreak100 from @NEJM here: https://t.co/YqGsDXd6Rd pic.twitter.com/kKQDbTsa5K
8a) Based on the above safety/activity @IASLC #WCLC22 #TrialsinProgress presented by @MLJohnsonMD2 et al. @SarahCannonDocs, WCLC EP08.02-111
— @onc_ce (@onc_ce) August 16, 2022
➡️SHP2i improved KRASG12C responses #xenograft studies!
➡️SHP2i ⬆️ innate/adaptive #immunity.
(cont) pic.twitter.com/OT8FaHJRM4
9a) @IASLC #WCLC22 Dr. Tuns presented (EP16.03-004) Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRASG12C Inhibition
— @onc_ce (@onc_ce) August 16, 2022
➡️ #HER2 overexpressing #KRASG12C cells resistant to #sotorasib
#LCSM: pic.twitter.com/lw2fDlnYiP
10) @IASLC #WCLC22 #Sotorasib w/immunotherapy Dr. Bob Li @MSKCancerCenter presented CodeBreak 100/101
— @onc_ce (@onc_ce) August 16, 2022
➡️Phase 1b Sotorasib + Pembro/Atezo (Lead In or Concurrent)
🛑G3>= TRAEs: 30-53% (lead in) vs 50-74% (concurrent), 2 grade 5‼️
➡️ORR: 29%
➡️mDOR: 17.9 mths (n=17)@KRASKickers pic.twitter.com/H22RgikZ0W
12) KRASG12C inhibitor #4 GDC-6036 Phase 1 study was presented #WCLC22 OA03.02 @IASLC
— @onc_ce (@onc_ce) August 16, 2022
➡️ TRAEs: 88%, Gr3 or > 17%, ‼️ LFTs
➡️ ORR #LCSM: 46%, mDOR: NR
➡️ Phase II/III study BFAST, vs docetaxel 🔜
➡️ QD dosing favorable, ⬇️ TRAEs vs others pic.twitter.com/uURiwfIemN
14) As we look forward, more 🎯💊 therapies with novel targets, combinations and KRASG12C ➖ in pipeline to hopefully will improve #outcomes, great checklist of desirable properties by @ElinardouHelena @IASLC #WCLC22
— @onc_ce (@onc_ce) August 16, 2022
@Oncoalert @KRASKickers pic.twitter.com/RPznuLsNsR
15b) Sneak peeks into some other interesting #concepts presented at #WCLC22 @IASLC
— @onc_ce (@onc_ce) August 16, 2022
(2/3)➡️ KRAS-Targeted Peptide Vaccine [EP08.01-086]
Coming 🔜 pic.twitter.com/CW4VJbl4Vq
16) We are entering an exciting era in #KRAS tx, the previously undruggable🎯, & hope to improve #outcomes for our patients. I am @ADesaiMD. That wraps up this module on #WCLC22 & #KRASG12C #LCSM highlights! I leave you with a #Onc1Slider summary of current #KRASG12C landscape pic.twitter.com/DJvoMosu4j
— @onc_ce (@onc_ce) August 16, 2022
17) Now go to https://t.co/EnE73Ke9dS to claim your 🆓CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. FOLLOW US here @onc_ce for more #accredited #tweetorials by expert authors! pic.twitter.com/sOEFfx3pxr
— @onc_ce (@onc_ce) August 16, 2022